The role of the human immune monitoring core (HIMC, Core C) will be to (1) provide standardized, state-ofthe art Immune monitoring assays at the RNA, protein, and cellular level, to support research projects within the U19;(2) to test and develop new technologies for immune monitoring that may be useful In the context of the U19;and (3) to efficiently archive, report, and mine data from immune monitoring studies, so as to increase the value of the data and to assist In biomarker discovery.
Specific Aim 1 : Standardized, state-of-the-art immune monitoring assays. The HIMC has validated a set of Immune monitoring assays that will be available to U19 research projects. These include genome-wide RNA microarrays, multiplex Luminex cytokine assays, immunophenotyping, phosphoepitope flow cytometry, CFSE dye dilution assays for proliferation, and intracellular cytokine staining. An ELISPOT reader is also available for readout of ELISPOT assays.
Specific Aim 2 : New technology for immune monitoring. The HIMC is evaluating multiple new platforms with potential for immune monitoring, including: isoelectric focusing analysis of phosphoproteins (CellBiosciences);chemiluminescent cytokine detection (MesoScale Discovery);biomolecular interaction analysis (ForteBlo);multiplexed tetramer analysis;flow cytometry with time-of-flight mass spectrometry (CyTof);qPCR arrays on sorted cell populations (Fluidigm Blomark);and specialized microarrays for Immunologically relevant genes and for pathogen detection (Agilent).
Specific Aim 3 : Databaslng. The HIMC is Implementing the use of collaborative online databases for flow cytometry, Luminex, and microarray data, and is also evaluating data aggregation and mining programs such as Tibco Spotfire.
The use of standardized assays and data management will facilitate mining across studies and greatly Increase the value of the data for discovery of new biomarkers of vaccine efficacy and disease protection. New technology developed may create opportunities to discover such biomarkers In ways not possible before.
|Qi, Qian; Liu, Yi; Cheng, Yong et al. (2014) Diversity and clonal selection in the human T-cell repertoire. Proc Natl Acad Sci U S A 111:13139-44|
|Chang, Serena; Kohrt, Holbrook; Maecker, Holden T (2014) Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother 63:713-9|
|Qi, Qian; Zhang, David W; Weyand, Cornelia M et al. (2014) Mechanisms shaping the naïve T cell repertoire in the elderly - thymic involution or peripheral homeostatic proliferation? Exp Gerontol 54:71-4|
|Shekhar, Karthik; Brodin, Petter; Davis, Mark M et al. (2014) Automatic Classification of Cellular Expression by Nonlinear Stochastic Embedding (ACCENSE). Proc Natl Acad Sci U S A 111:202-7|
|Jackson, Katherine J L; Liu, Yi; Roskin, Krishna M et al. (2014) Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. Cell Host Microbe 16:105-14|
|Lu, Yuan; Welsh, John P; Swartz, James R (2014) Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc Natl Acad Sci U S A 111:125-30|
|Wang, Chen; Liu, Yi; Xu, Lan T et al. (2014) Effects of aging, cytomegalovirus infection, and EBV infection on human B cell repertoires. J Immunol 192:603-11|
|O'Gorman, William E; Huang, Huang; Wei, Yu-Ling et al. (2014) The Split Virus Influenza Vaccine rapidly activates immune cells through Fc? receptors. Vaccine 32:5989-97|
|Rosenberg-Hasson, Yael; Hansmann, Leo; Liedtke, Michaela et al. (2014) Effects of serum and plasma matrices on multiplex immunoassays. Immunol Res 58:224-33|
|Kay, Alexander W; Fukuyama, Julia; Aziz, Natali et al. (2014) Enhanced natural killer-cell and T-cell responses to influenza A virus during pregnancy. Proc Natl Acad Sci U S A 111:14506-11|
Showing the most recent 10 out of 40 publications